($LTRN) Lantern Just Released a New Corporate Presentation. One Slide Stood Out!

Most people still seem to view Lantern as “the LP-300 company.”

Their latest corporate deck suggests management sees the future very differently:

1. LP-300 (Phase 2)
2. LP-184 (multiple planned Phase 1b/2 trials)
3. RADR AI platform
4. withZeta AI research platform

What’s interesting is that Lantern describes the goal as creating partnering and licensing opportunities, not necessarily commercializing everything alone.

BIO 2026 starts today and CEO Panna Sharma is participating in an executive roundtable with biotech leaders and investors.

Worth watching.